tiprankstipranks
Trending News
More News >
Apimeds Pharmaceuticals US, Inc. (APUS)
:APUS
US Market

Apimeds Pharmaceuticals US, Inc. (APUS) Income Statement

Compare
17 Followers

Apimeds Pharmaceuticals US, Inc. Income Statement

Last quarter (Q3 2025), Apimeds Pharmaceuticals US, Inc.'s total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Apimeds Pharmaceuticals US, Inc.'s net income was $-1.78M. See Apimeds Pharmaceuticals US, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 1.28M$ 747.44K$ 639.53K$ 1.02M
Depreciation and Amortization
$ 0.00$ 0.00$ 0.00$ 0.00
EBITDA
$ -1.27M$ -739.63K$ -639.53K$ -1.02M
Operating Income
$ -1.28M$ -747.44K$ -639.53K$ -1.02M
Other Income/Expenses
$ -114.89K$ -30.26K$ -29.14K$ -6.74K
Pretax Income
$ -1.39M$ -777.69K$ -668.67K$ -1.03M
Net Income
$ -1.39M$ -777.69K$ -668.67K$ -1.03M
Per Share Metrics
Basic EPS
$ -0.12$ -0.07$ -0.06$ -0.09
Diluted EPS
$ -0.11$ -0.07$ -0.06$ -0.09
Weighted Average Shares Outstanding
11.53M 11.53M 11.53M 11.53M
Weighted Average Shares Outstanding (Diluted)
12.69M 12.69M 12.69M 12.69M
Currency in USD

Apimeds Pharmaceuticals US, Inc. Earnings and Revenue History